Fractalkine-CX3CR1 Axis in Periodontal Therapy

Thirty stage 3 periodontitis, thirty gingivitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; gingivitis and periodontitis patients underwent non-surgical periodontal treatment, and GCF samples were collected at baseline and at 1 and 3 months after treatment. CX3CL1 and CX3CR1 were determined by ELISA.

Inclusion criteria

• 25-50 years of age
• having at least 20 natural teeth, excluding third molars
• having no systemic disease
• non-smokers
• criteria for healthy control group: BOP < 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction
• criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.

Exclusion criteria

• having any systemic diseases,
• smoking
• current pregnancy or lactation
• a history of periodontal treatment in the past 6 months
• using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.